Evidence map›Paper›PMID 41784503›Full record

ArticleMicrobiology spectrum2026

Evaluation of commercial susceptibility testing methods for

Stefano Mancini, NARA Network members, Dominique S Blanc, Silvio D Brugger, Sari Rasheed, Markus Jutzi, Natalia Kolesnik-Goldmann, Rolf Mueller, Adrian Egli, Vladimira Hinic and 1 more

Abstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Stefano ManciniInstitute of Medical Microbiology, University of Zurich, Zurich, Switzerland.ORCID 0000-0003-4516-5952
NARA Network members
Dominique S BlancInstitute of Medical Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-0324-8437
Silvio D BruggerDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0001-9492-9088
Sari RasheedHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), Saarland University, Saarbrücken, Germany.ORCID 0000-0002-9700-0474
Markus JutziAnalytica Medizinische Laboratorien AG, Zurich, Switzerland.
Natalia Kolesnik-GoldmannInstitute of Medical Microbiology, University of Zurich, Zurich, Switzerland.
Rolf MuellerHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), Saarland University, Saarbrücken, Germany.ORCID 0000-0002-1042-5665
Adrian EgliInstitute of Medical Microbiology, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-3564-8603
Vladimira HinicInstitute of Medical Microbiology, University of Zurich, Zurich, Switzerland.
Oliver NolteInstitute of Medical Microbiology, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-1761-0812

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 211422Universitätsspital Zürich USZF270808
6 · The paper itself

Abstract

Vancomycin-resistant IMPORTANCE: Vancomycin-resistant

Indexed as

Anti-Bacterial AgentsDaptomycinEnterococcus faeciumVancomycin-Resistant EnterococciGram-Positive Bacterial InfectionsHumansMicrobial Sensitivity TestsAnti-Bacterial AgentsDaptomycinbroth microdilutiondaptomycin ASTgradient diffusion testvancomycin-resistant Enterococcus faecium

Identifiers

PMID41784503
PMCPMC13055354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.